An extension study to evaluate the persistence of the immune responses induced by GSK Biologicals Zoster Vaccine, GSK324332A, administered in healthy adult subjects aged 18-30 years and 50-70 years.
Phase of Trial: Phase II
Latest Information Update: 08 Apr 2019
At a glance
- Drugs Varicella zoster virus glycoprotein vaccine (Primary) ; AS01B; Varicella zoster virus vaccine live
- Indications Herpes zoster
- Focus Pharmacodynamics
- Sponsors GlaxoSmithKline
- 08 Apr 2019 Results published in the Vaccine
- 12 Oct 2008 Trial phase changed from I/II to II as reported by ClinicalTrials.gov.
- 09 Sep 2008 Actual patient number (34) added as reported by ClinicalTrials.gov.